



SUMMARY OF CHANGES
Amendment #9, Version Date: August 10, 2007

RTOG 0132, "A Phase II Trial of Neoadjuvant/Adjuvant STI-571 (GLEEVEC NSC #716051) For Primary and Recurrent Operable Malignant GIST Expressing the KIT Receptor Tyrosine Kinase (CD117) [ACRIN 6665]"

Study Chair: Burton Eisenberg, M.D., (603) 653-3614; FAX# (603) 653-9003;
Burton.L.Eisenberg@Dartmouth.edu

The Pharmaceutical Management Branch (PMB) of the NCI has notified RTOG that STI-571 (imatinib) will be provided in tablets rather than capsules. The PMB requires that **RTOG 0132** be amended accordingly.

The following changes have been made:

- **Section 7.1:** In the first sentence of the second paragraph, the word "capsules" was replaced with "tablets."
- **Section 7.2.4.1:** "How Supplied" was amended with text provided by PMB.
- **Section 7.2.4.2:** The heading of the section was amended from "Storage" to "Storage/Stability", and the section was amended with text provided by PMB.